Abstract
Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Volume: 11 Issue: 1
Author(s): Wei-Hua Yan
Affiliation:
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Abstract: Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Export Options
About this article
Cite this article as:
Yan Wei-Hua, HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187153011794982059
DOI https://dx.doi.org/10.2174/187153011794982059 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design An Overview on the Pharmacokinetics of Quantum Dots
Current Drug Metabolism Polymeric Radiotracers in Nuclear Imaging
Current Drug Delivery The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Applications of X-Ray Diffraction Imaging to Mammography
Recent Patents on Medical Imaging Meet Our Executive Editor
Current Traditional Medicine Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Mesenchymal Stem Cells for Treatment of CNS Injury
Current Neuropharmacology Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology TRPV1 Antagonists as a Potential Treatment for Hyperalgesia
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on DNA & Gene Sequences A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry